Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01449058
Title A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | GBR | FRA | ESP | CHE | AUS

Facility Status City State Zip Country Details
University of California San Diego - Moores Cancer Center Dept Onc La Jolla California 92093-0658 United States Details
H. Lee Moffitt Cancer Center & Research Institute H. Lee Moffitt SC Tampa Florida 33612 United States Details
Northwestern Memorial Hospital Chicago Illinois 60611 United States Details
Massachusetts General Hospital CCPO Boston Massachusetts 02114 United States Details
Memorial Sloan Kettering Cancer Center Onc. Dept New York New York 90033 United States Details
Montefiore Medical Center SC The Bronx New York 10461 United States Details
University of Texas/MD Anderson Cancer Center Dept. of Onc. Houston Texas 77030-4009 United States Details
University of Utah / Huntsman Cancer Institute Huntsman (3) Salt Lake City Utah 84103 United States Details
Array BioPharma Investigative Site Parkville Victoria 3050 Australia Details
Array BioPharma Investigative Site Villejuif Cedex 94805 France Details
Array BioPharma Investigative Site Milano MI 20133 Italy Details
Array BioPharma Investigative Site Roma RM 00168 Italy Details
Array BioPharma Investigative Site Barcelona Catalunya 08035 Spain Details
Array BioPharma Investigative Site Barcelona Catalunya 08036 Spain Details
Array BioPharma Investigative Site Bellinzona 6500 Switzerland Details
Array BioPharma Investigative Site Sutton SM2 5PT United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field